Land: Malta
Sprache: Englisch
Quelle: Medicines Authority
CHORIONIC GONADOTROPHIN, HUMAN
Ferring SPA Via Senigallia 18/2, Milan, Italy
G03GA01
CHORIONIC GONADOTROPHIN, HUMAN 5000 IU
POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
CHORIONIC GONADOTROPHIN, HUMAN 5000 IU
POM
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Withdrawn
2006-09-20
Directions for use Please read carefully! Choragon® 5000 COMPOSITION 1 Ampoule with dry substance contains 5000 IU human chorionic gonadotrophin (HCG) as the active ingredient and mannitol as further ingredient. 1 Ampoule with 1ml solvent contains isotonic sodium chloride solution and dilute hydrochloric acid for PH-adjustment. INDICATIONS _Female:_ - induction of ovulation, e.g. after stimulation of follicle growth._ _ - maintenance of corpus luteum function in female patients with luteal phase insufficiency. _Male:_ _- _delayed puberty, hypogonadotrophic hypogonadism. _As a diagnostic agent:_ - in children to differentiate between cryptorchism and anarchism._ _ - to assess the function of the testes in patients with hypogonadotrophic hypogonadism before a planned long-term stimulation treatment (Leydig-cell function test). CONTRAINDICATIONS _Female:_ - If ovarian hyperstimulation is present, HCG should not be used to induce ovulation._ _ - Tumors affected by sexual hormones. - Ovarian, uterine or mammary carcinoma - Extrauterine pregnancy in the last 3 months. - Gynaecological haemorrhage of unknown aetiology. - Hypersensitivity against chorionic gonadotrophin or any of the excipients of Choragon®. - Active thromboembolic disease. - _Male:_ - Tumors affected by sexual hormones._ _ - Hypersensitivity against chorionic gonadotrophin or any of the excipients of Choragon®. - Active thromboembolic disease. Choragon® must not be administered in case the treatment outcome is unlikely to be favourable, e.g. in case of: - Primary ovarian failure. - Malformations of sexual organs incompatible with pregnancy. - Uterine myoma incompatible with pregnancy. - Woman after menopause. Choragon® should not be administe Lesen Sie das vollständige Dokument
Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Choragon® 5000 2. QUALITATIVE UND QUANTITATIVE COMPOSITION 1 ampoule of Choragon 5000 contains 5000 IU chorionic gonadotrophin. For excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Choragon 5000 Therapy _ Gynaecology _ • Ovulation induction, if necessary after stimulation of follicle growth Maintenance of the corpus luteum function in female patients with luteal phase insufficiency. _ Paediatrics _ • Delayed puberty in boys. Diagnostics Differential diagnosis of cryptorchism and anorchism. Assessment of the function of the testes in patients with hypogonadotropic hypogonadism before a planned long-term stimulation treatment. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Method of administration After solution in the enclosed solvent, Choragon is injected intramuscularly Dosage, duration of administration Choragon 5000 Gynaecology For ovulation induction once 1 or 2 ampoules of Choragon 5000, if the dominant follicle has reached a diameter of more than 18mm. For maintenance of the corpus luteum function, three times I ampoule Choragon 5000, e.g. on the 3rd, 6th and 9th day following ovulation. Page 2 of 7 Paediatrics and andrologv For induction of puberty in boys with delayed puberty 1 ampoule of Choragon 5000 per week over a period of 3 months. Once 1 ampoule of Choragon 5000 - for differential diagnosis in boys with undescended testicle as well as - for assessment of the function of the testes in patients with hypogonadotropic hypogonadism. 4.3 CONTRAINDICATIONS General Lesen Sie das vollständige Dokument